tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyMonopar Therapeutics initiated with an Overweight at Morgan Stanley
2M ago
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
Premium
Ratings
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
2M ago
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
4M ago
Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
PremiumThe FlyCoinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
4M ago
Monopar Therapeutics Unveils Promising Phase 2 Study Results
Premium
Company Announcements
Monopar Therapeutics Unveils Promising Phase 2 Study Results
4M ago
Monopar Therapeutics initiated with an Outperform at Leerink
Premium
The Fly
Monopar Therapeutics initiated with an Outperform at Leerink
4M ago
Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications
PremiumCompany AnnouncementsMonopar Therapeutics’ Innovative Imaging Agent Study: Market Implications
4M ago
Monopar Therapeutics initiated with an Overweight at Barclays
Premium
The Fly
Monopar Therapeutics initiated with an Overweight at Barclays
5M ago
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
Premium
Ratings
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100